AMAG Pharmaceuticals price target lowered to $30 from $43 at Summer Street Summer Street lowered its price target for AMAG Pharmaceuticals to $30 following the company's complete response letter for a broader indication of Feraheme. The firm keeps a Buy rating on the stock.
AMAG Pharmaceuticals transferred with a Market Perform at FBR Capital FBR Capital transferred coverage of AMAG Pharmaceuticals with a Market Perform rating, a downgrade from its previous rating of Outperform. FBR believes Feraheme growth will be limited to market share gains and that Makena expectations are fully realized at current valuation levels. The firm has a $42 price target for AMAG shares.